LU93312I2 - MIGALASTAT OR SALT THEREOF, INCLUDING SALT OF CHLORHYDRATE - Google Patents

MIGALASTAT OR SALT THEREOF, INCLUDING SALT OF CHLORHYDRATE Download PDF

Info

Publication number: LU93312I2
Authority: LU; Luxembourg
Prior art keywords: salt; migalastat; chlorhydrate; including salt
Prior art date: 2006-05-16

Application number

LU93312C

Other languages

French (fr)

Original Assignee

Amicus Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-16

Filing date

2016-11-16

Publication date

2017-01-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93312(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-11-16 Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc

2017-01-26 Publication of LU93312I2 publication Critical patent/LU93312I2/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
- G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Ecology (AREA)
Pathology (AREA)
Tropical Medicine & Parasitology (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Obesity (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LU93312C 2006-05-16 2016-11-16 MIGALASTAT OR SALT THEREOF, INCLUDING SALT OF CHLORHYDRATE LU93312I2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US80108906P	2006-05-16	2006-05-16
US85363106P	2006-10-23	2006-10-23
PCT/US2007/069046 WO2007137072A2 (en)	2006-05-16	2007-05-16	Assays for diagnosing and evaluating treatment options for fabry disease

Publications (1)

Publication Number	Publication Date
LU93312I2 true LU93312I2 (en)	2017-01-26

Family

ID=38723987

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU93312C LU93312I2 (en)	2006-05-16	2016-11-16	MIGALASTAT OR SALT THEREOF, INCLUDING SALT OF CHLORHYDRATE

Country Status (19)

Country	Link
US (9)	US7851143B2 (en)
EP (6)	EP2533050B3 (en)
JP (7)	JP2009537149A (en)
AU (1)	AU2007253900A1 (en)
CA (1)	CA2652553C (en)
CY (3)	CY1115180T1 (en)
DK (3)	DK2533050T6 (en)
ES (4)	ES2573498T3 (en)
FI (1)	FI3457135T3 (en)
HK (1)	HK1218955A1 (en)
HU (3)	HUE071237T2 (en)
LT (2)	LT3457135T (en)
LU (1)	LU93312I2 (en)
MX (2)	MX351004B (en)
NL (1)	NL300843I2 (en)
PL (3)	PL2787345T3 (en)
PT (2)	PT2533050E (en)
SI (3)	SI2787345T1 (en)
WO (1)	WO2007137072A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2573498T3 (en)	2006-05-16	2016-06-08	Amicus Therapeutics, Inc.	Treatment options for Fabry's disease
US9999618B2 (en)	2007-04-26	2018-06-19	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2150254A4 (en) *	2007-04-26	2010-11-10	Amicus Therapeutics Inc	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
SI3470077T1 (en) *	2008-02-12	2020-12-31	Amicus Therapeutics, Inc.	Method to predict response to pharmacological chaperone treatment of diseases
US20110136151A1 (en) *	2008-03-12	2011-06-09	Amicus Therapeutics, Inc.	Assays for diagnosing and evaluating treatment options for pompe disease
JP5739898B2 (en) *	2009-11-17	2015-06-24	ベイラーリサーチインスティテュートＢａｙｌｏｒＲｅｓｅａｒｃｈＩｎｓｔｉｔｕｔｅ	Urinary triosylceramide (GB3) as a heart disease marker
EP2542687A1 (en) *	2010-03-05	2013-01-09	Baylor Research Institute	Involvement of androgen/androgen receptor pathway in fabry disease
CN103974619B (en) *	2011-03-11	2017-02-15	阿米库斯治疗学公司	Dosing regimens for the treatment of Fabry disease
DK2707101T3 (en)	2011-05-12	2019-05-13	Proteostasis Therapeutics Inc	PROTEOSTASE REGULATORS
CA2860085A1 (en) *	2011-12-22	2013-06-27	Centogene Ip Gmbh	Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
CA2861464C (en)	2012-01-25	2018-03-06	Proteostasis Therapeutics, Inc.	Proteasome activity modulating tricyclic compounds
WO2014127038A1 (en) *	2013-02-12	2014-08-21	Baylor Research Institute	Methods and compositions related to calcium homeostasis and fabry disease
NZ720499A (en) *	2013-12-23	2020-04-24	Bcn Peptides Sa	Bicalutamide analogs or (s)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis
US9675627B2 (en) *	2014-04-14	2017-06-13	Amicus Therapeutics, Inc.	Dosing regimens for treating and/or preventing cerebral amyloidoses
US9957494B2 (en)	2014-07-25	2018-05-01	Shire Human Genetic Therapies, Inc.	Crystal structure of human four-phosphate adaptor protein 2 glycolipid transfer protein like domain
GB201508025D0 (en)	2015-05-11	2015-06-24	Ucl Business Plc	Fabry disease gene therapy
AR109103A1 (en) *	2016-07-19	2018-10-31	Amicus Therapeutics Inc	TREATMENT OF FABRY'S DISEASE IN PATIENTS NOT TREATED AND PREVIOUSLY TREATED WITH ERT
US12020820B1 (en)	2017-03-03	2024-06-25	Cerner Innovation, Inc.	Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en)	2017-03-06	2022-05-17	Cerner Innovation, Inc.	Predicting glycogen storage diseases (Pompe disease) and decision support
CA3224537C (en)	2017-05-30	2025-09-09	Amicus Therapeutics, Inc.	Use of migalastat in the treatment of fabry patients having renal impairment
PT4324522T (en) *	2017-05-30	2026-03-13	Amicus Therapeutics Inc	Treatment methods for patients with Fabry disease and renal failure.
US11923048B1 (en)	2017-10-03	2024-03-05	Cerner Innovation, Inc.	Determining mucopolysaccharidoses and decision support tool
SMT202400027T1 (en) *	2018-02-06	2024-03-13	Amicus Therapeutics Inc	Treatment of patients with classic fabry disease with migalastat
CA3090496C (en)	2018-02-06	2024-03-26	Amicus Therapeutics, Inc.	Use of migalastat for treating fabry disease in pregnant patients
CN112585130A (en)	2018-06-27	2021-03-30	蛋白质平衡治疗股份有限公司	Proteasome activity enhancing compounds
BR112020026580A2 (en)	2018-06-27	2021-03-23	Proteostasis Therapeutics, Inc. (Fem)	COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATING A PATIENT
US20220184185A1 (en)	2018-07-25	2022-06-16	Modernatx, Inc.	Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
EP4282472A3 (en)	2018-08-20	2024-02-21	Amicus Therapeutics, Inc.	Methods of treating fabry disease in patients having a mutation in the gla gene
EP3851105B1 (en)	2019-08-07	2026-03-04	Amicus Therapeutics, Inc.	Migalastat for use in treating fabry disease in patients having a mutation in the gla gene
US11191827B1 (en)	2020-12-09	2021-12-07	Tevogen Bio Inc.	COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
US11623916B2 (en)	2020-12-16	2023-04-11	Amicus Therapeutics, Inc.	Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0463109A4 (en) *	1989-03-24	1992-11-19	Research Corporation Technologies, Inc.	Recombinant alpha-galactosidase, a therapy for fabry disease
CA2086413A1 (en)	1990-06-29	1991-12-30	Yohji Ezure	Piperidine derivatives
CA2250780A1 (en)	1996-04-10	1997-10-16	The Regents Of The University Of California	Correction of genetic defects using chemical chaperones
US6270954B1 (en)	1996-04-10	2001-08-07	The Regents Of The University Of California	Correction of genetic defects using chemical chaperones
US6274597B1 (en)	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
US7842470B2 (en)	2001-10-09	2010-11-30	Oregon Health & Science University	Method for pharmacoperones correction of GnRHR mutant protein misfolding
PT2441467E (en)	2003-01-31	2015-10-12	Sinai School Medicine	Combination therapy for treating protein deficiency disorders
US7446098B2 (en) *	2003-02-18	2008-11-04	Mount Sinai School Of Medicine Of New York University	Combination therapy for treating protein deficiencies
US20070066543A1 (en) *	2003-05-22	2007-03-22	The Hospital For Sick Children	Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
FR2861991B1 (en)	2003-11-07	2008-01-18	Centre Nat Rech Scient	USE OF GLUCOSIDASE INHIBITORS FOR MUCOVISCIDOSE THERAPY
EP1682504B1 (en)	2003-11-12	2012-12-26	Amicus Therapeutics Inc.	Hydroxy piperidine derivatives to treat gaucher disease
EP2932982B1 (en)	2005-05-17	2018-10-03	Amicus Therapeutics, Inc.	A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
PL2027137T3 (en)	2005-06-08	2015-08-31	Amicus Therapeutics Inc	Imino and amino sugar purification
CN101541172A (en)	2005-06-08	2009-09-23	阿米库斯治疗学公司	Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
AU2006272497B2 (en)	2005-07-27	2012-07-19	University Of Florida Research Foundation, Inc.	Small compounds that correct protein misfolding and uses thereof
US7790364B2 (en)	2006-01-27	2010-09-07	The Board Of Trustees Of The Leland Stanford Junior University	Compositions and methods for high throughput screening of pharmacological chaperones
ES2573498T3 (en)	2006-05-16	2016-06-08	Amicus Therapeutics, Inc.	Treatment options for Fabry's disease
UA94624C2 (en)	2006-09-22	2011-05-25	Крка, Товарна Здравіл, Д.Д., Ново Мєсто	Aripiprazole hemifumarate and process for its preparation
AU2008232614A1 (en)	2007-03-30	2008-10-09	Amicus Therapeutics, Inc.	Method for the treatment of Fabry disease using pharmacological chaperones
US9999618B2 (en)	2007-04-26	2018-06-19	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2150254A4 (en)	2007-04-26	2010-11-10	Amicus Therapeutics Inc	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
SI3470077T1 (en)	2008-02-12	2020-12-31	Amicus Therapeutics, Inc.	Method to predict response to pharmacological chaperone treatment of diseases
US8321148B2 (en)	2008-10-24	2012-11-27	Amicus Therapeutics, Inc.	Multiple compartment dosing model
US9206457B2 (en)	2009-05-26	2015-12-08	Amicus Therapeutics, Inc.	Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
US20110070643A1 (en)	2009-05-26	2011-03-24	Do Hung V	Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
JP5739898B2 (en)	2009-11-17	2015-06-24	ベイラーリサーチインスティテュートＢａｙｌｏｒＲｅｓｅａｒｃｈＩｎｓｔｉｔｕｔｅ	Urinary triosylceramide (GB3) as a heart disease marker
CN103974619B (en)	2011-03-11	2017-02-15	阿米库斯治疗学公司	Dosing regimens for the treatment of Fabry disease
US10155027B2 (en)	2012-07-17	2018-12-18	Amicus Therapeutics, Inc.	Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
HK1209625A1 (en)	2012-07-17	2016-04-08	Amicus Therapeutics, Inc.	Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
KR102004114B1 (en)	2016-03-22	2019-07-26	아미쿠스 세라퓨틱스, 인코포레이티드	Methods for the treatment of Fabry disease in patients with G9331A mutations in the GLA gene
AR109103A1 (en)	2016-07-19	2018-10-31	Amicus Therapeutics Inc	TREATMENT OF FABRY'S DISEASE IN PATIENTS NOT TREATED AND PREVIOUSLY TREATED WITH ERT
TW201829770A (en)	2017-01-10	2018-08-16	美商阿米庫斯醫療股份有限公司	Recombinant alpha-galactosidase a for treatment of fabry disease
CA3224537C (en)	2017-05-30	2025-09-09	Amicus Therapeutics, Inc.	Use of migalastat in the treatment of fabry patients having renal impairment
WO2019017938A1 (en)	2017-07-19	2019-01-24	Amicus Therapeutics, Inc.	Treatment of fabry disease in ert-naïve and ert-experienced patients
IL272893B2 (en)	2017-08-28	2024-07-01	Amicus Therapeutics Inc	Methods for increasing and/or stabilizing cardiac functions in patients with Fabry disease
SMT202400027T1 (en)	2018-02-06	2024-03-13	Amicus Therapeutics Inc	Treatment of patients with classic fabry disease with migalastat
CA3090496C (en)	2018-02-06	2024-03-26	Amicus Therapeutics, Inc.	Use of migalastat for treating fabry disease in pregnant patients
EP4282472A3 (en)	2018-08-20	2024-02-21	Amicus Therapeutics, Inc.	Methods of treating fabry disease in patients having a mutation in the gla gene
AR120055A1 (en)	2019-06-11	2022-02-02	Amicus Therapeutics Inc	METHODS TO TREAT FABRY'S DISEASE IN PATIENTS WITH KIDNEY FAILURE
EP3851105B1 (en)	2019-08-07	2026-03-04	Amicus Therapeutics, Inc.	Migalastat for use in treating fabry disease in patients having a mutation in the gla gene

2007
- 2007-05-16 ES ES14168748.3T patent/ES2573498T3/en active Active
- 2007-05-16 DK DK12168451.8T patent/DK2533050T6/en active
- 2007-05-16 EP EP12168451.8A patent/EP2533050B3/en active Active
- 2007-05-16 EP EP15173515.6A patent/EP2955520B1/en active Active
- 2007-05-16 AU AU2007253900A patent/AU2007253900A1/en not_active Abandoned
- 2007-05-16 EP EP07797506.8A patent/EP2024745B1/en active Active
- 2007-05-16 CA CA2652553A patent/CA2652553C/en active Active
- 2007-05-16 WO PCT/US2007/069046 patent/WO2007137072A2/en not_active Ceased
- 2007-05-16 MX MX2013006681A patent/MX351004B/en unknown
- 2007-05-16 DK DK18197135.9T patent/DK3457135T3/en active
- 2007-05-16 HU HUE18197135A patent/HUE071237T2/en unknown
- 2007-05-16 PT PT121684518T patent/PT2533050E/en unknown
- 2007-05-16 DK DK14168748.3T patent/DK2787345T3/en active
- 2007-05-16 PL PL14168748T patent/PL2787345T3/en unknown
- 2007-05-16 ES ES18197135T patent/ES3012794T3/en active Active
- 2007-05-16 US US11/749,512 patent/US7851143B2/en active Active
- 2007-05-16 PL PL18197135.9T patent/PL3457135T3/en unknown
- 2007-05-16 LT LTEP18197135.9T patent/LT3457135T/en unknown
- 2007-05-16 ES ES15173515T patent/ES2709445T3/en active Active
- 2007-05-16 MX MX2008014679A patent/MX2008014679A/en active IP Right Grant
- 2007-05-16 EP EP18197135.9A patent/EP3457135B1/en active Active
- 2007-05-16 FI FIEP18197135.9T patent/FI3457135T3/en active
- 2007-05-16 EP EP24217103.1A patent/EP4541418A3/en active Pending
- 2007-05-16 SI SI200731776A patent/SI2787345T1/en unknown
- 2007-05-16 SI SI200732206T patent/SI3457135T1/en unknown
- 2007-05-16 EP EP14168748.3A patent/EP2787345B8/en active Active
- 2007-05-16 PT PT181971359T patent/PT3457135T/en unknown
- 2007-05-16 JP JP2009511222A patent/JP2009537149A/en active Pending
- 2007-05-16 PL PL12168451T patent/PL2533050T6/en unknown
- 2007-05-16 SI SI200731457T patent/SI2533050T1/en unknown
- 2007-05-16 HU HUE14168748A patent/HUE027569T2/en unknown
- 2007-05-16 ES ES12168451.8T patent/ES2464527T7/en active Active
2010
- 2010-12-13 US US12/966,904 patent/US20110104727A1/en not_active Abandoned
2012
- 2012-04-12 US US13/445,338 patent/US9000011B2/en active Active
- 2012-12-27 JP JP2012285265A patent/JP6026268B2/en active Active
2014
- 2014-05-27 CY CY20141100377T patent/CY1115180T1/en unknown
2015
- 2015-03-09 US US14/641,707 patent/US9480682B2/en active Active
- 2015-07-31 JP JP2015151795A patent/JP2016006088A/en not_active Withdrawn
2016
- 2016-05-24 CY CY20161100448T patent/CY1117656T1/en unknown
- 2016-06-15 HK HK16106878.6A patent/HK1218955A1/en unknown
- 2016-10-31 US US15/338,923 patent/US9987263B2/en active Active
- 2016-11-11 NL NL300843C patent/NL300843I2/nl unknown
- 2016-11-15 CY CY2016040C patent/CY2016040I1/en unknown
- 2016-11-16 LU LU93312C patent/LU93312I2/en unknown
- 2016-11-16 HU HUS1600048C patent/HUS1600048I1/en unknown
- 2016-11-16 LT LTPA2016033C patent/LTC2787345I2/en unknown
2018
- 2018-04-10 JP JP2018075570A patent/JP6800176B2/en active Active
- 2018-05-08 US US15/974,217 patent/US10383864B2/en active Active
- 2018-05-08 US US15/974,222 patent/US10406143B2/en active Active - Reinstated
2019
- 2019-09-09 US US16/564,694 patent/US11241422B2/en active Active
2020
- 2020-07-27 JP JP2020126185A patent/JP7175297B2/en active Active
2022
- 2022-02-07 US US17/665,969 patent/US20220160690A1/en active Pending
- 2022-11-08 JP JP2022178697A patent/JP2023027053A/en active Pending
2024
- 2024-12-13 JP JP2024218337A patent/JP2025060691A/en active Pending

Also Published As

Publication number	Publication date
PT3457135T (en)	2025-02-04
MX2008014679A (en)	2009-04-14
EP2787345B1 (en)	2016-02-24
EP2024745B1 (en)	2015-07-08
JP2023027053A (en)	2023-03-01
CY2016040I2 (en)	2017-06-28
EP2533050B3 (en)	2015-06-24
JP6800176B2 (en)	2020-12-16
CA2652553A1 (en)	2007-11-29
LT3457135T (en)	2025-05-12
US11241422B2 (en)	2022-02-08
EP2955520A1 (en)	2015-12-16
DK2787345T3 (en)	2016-05-30
JP2016006088A (en)	2016-01-14
JP2025060691A (en)	2025-04-10
US9480682B2 (en)	2016-11-01
JP2020196717A (en)	2020-12-10
US20170042868A1 (en)	2017-02-16
WO2007137072A2 (en)	2007-11-29
PL2787345T3 (en)	2016-08-31
US20120220632A1 (en)	2012-08-30
EP2533050A1 (en)	2012-12-12
EP3457135B1 (en)	2024-12-04
EP2024745A4 (en)	2010-03-17
LTC2787345I2 (en)	2017-10-10
SI3457135T1 (en)	2025-07-31
JP7175297B2 (en)	2022-11-18
US20220160690A1 (en)	2022-05-26
CY1115180T1 (en)	2016-12-14
CY2016040I1 (en)	2017-06-28
SI2787345T1 (en)	2016-08-31
DK3457135T3 (en)	2025-02-24
US20180325881A1 (en)	2018-11-15
EP2024745A2 (en)	2009-02-18
DK2533050T6 (en)	2015-09-21
US20080056994A1 (en)	2008-03-06
EP4541418A3 (en)	2025-07-09
US7851143B2 (en)	2010-12-14
JP2013100307A (en)	2013-05-23
CY1117656T1 (en)	2017-05-17
US20190388409A1 (en)	2019-12-26
HUE071237T2 (en)	2025-08-28
JP6026268B2 (en)	2016-11-16
US20180250279A1 (en)	2018-09-06
EP3457135A1 (en)	2019-03-20
US10383864B2 (en)	2019-08-20
ES2709445T3 (en)	2019-04-16
HUE027569T2 (en)	2016-10-28
CA2652553C (en)	2020-08-18
JP2009537149A (en)	2009-10-29
PT2533050E (en)	2014-05-26
MX351004B (en)	2017-09-26
ES2464527T7 (en)	2015-09-14
LTPA2016033I1 (en)	2016-12-12
US9000011B2 (en)	2015-04-07
US9987263B2 (en)	2018-06-05
DK2533050T3 (en)	2014-06-02
US20150238474A1 (en)	2015-08-27
NL300843I2 (en)	2016-12-21
US20110104727A1 (en)	2011-05-05
ES2464527T9 (en)	2015-07-24
HK1129458A1 (en)	2009-11-27
US10406143B2 (en)	2019-09-10
EP2533050B1 (en)	2014-03-12
HK1218955A1 (en)	2017-03-17
HUS1600048I1 (en)	2017-01-30
ES3012794T3 (en)	2025-04-10
SI2533050T1 (en)	2014-07-31
ES2573498T3 (en)	2016-06-08
EP2955520B1 (en)	2018-10-31
AU2007253900A1 (en)	2007-11-29
WO2007137072A3 (en)	2008-10-16
EP4541418A2 (en)	2025-04-23
PL3457135T3 (en)	2025-06-09
PL2533050T6 (en)	2016-05-31
ES2464527T3 (en)	2014-06-03
JP2018138564A (en)	2018-09-06
PL2533050T3 (en)	2014-08-29
FI3457135T3 (en)	2025-03-08
HK1178975A1 (en)	2013-09-19
EP2787345B8 (en)	2016-04-13
EP2787345A1 (en)	2014-10-08

Publication	Publication Date	Title
LU93312I2 (en)	2017-01-26	MIGALASTAT OR SALT THEREOF, INCLUDING SALT OF CHLORHYDRATE
LU92568I2 (en)	2015-10-29	Simeprevir, or a salt of it, including sodium simeprevir
LU93327I2 (en)	2017-01-30	OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
LU92672I2 (en)	2015-11-02	FLURALANER OR ONE OF ITS SALTS
EP2298747A4 (en)	2012-06-13	DERIVATIVE OF TRIAZOLE OR SALT THEREOF
LU92864I2 (en)	2016-01-06	COBICISTAT OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS
LU92785I2 (en)	2015-11-03	CÉRITINIB OR A PHARAMCEUTICALLY ACCEPTABLE SALT THEREOF
BRPI0815588A2 (en)	2015-02-18	POLYORGANOSYLOXAN-POLYURERIA AND / OR POLYORGANOSYL-XANO-POLYURETHANE COMPOUNDS
EP2124523A4 (en)	2010-08-04	LINE OF LITTLE P2428-5006090
EP2042480A4 (en)	2011-11-23	DERIVED FROM AMINOINDANE OR SALT THEREOF
EP2149561A4 (en)	2011-09-07	DERIVATIVE OF TETRAHYDROISOQUINOLIN-1-ONE OR SALT THEREOF
BRPI0720547A2 (en)	2014-05-06	HETEROCYCLIC DERIVED METALOPROTEASE INHIBITORS
EP2110789A4 (en)	2010-12-01	PROCESSOR OF PAPER-CURRENCY
CR10809A (en)	2009-06-25	DERIVATIVES OF HETEROARIL-PIRROLIDINIL-Y-PIPERIDINIL-CETONA
DE602006009921D1 (en)	2009-12-03	Pigmented ceramic body
EP2062902A4 (en)	2010-11-17	LITHIUM SALT
EP1906944A4 (en)	2010-08-04	PREPARATION OF SCHISANDRINE B
NO20055643D0 (en)	2005-11-29	Preparation of lodixanol
PT1763520E (en)	2009-03-23	USE OF TRISSUBSTITUED BENZOPIRANONES
DE502007003774D1 (en)	2010-06-24	SHANK
EP2013346A4 (en)	2010-09-01	SPECIES OF PESTIVIRUS
EP1910272A4 (en)	2010-08-04	INHIBITORS OF THE RENINE
ITMI20061048A1 (en)	2007-11-30	PROCEDURE FOR THE PREPARATION OF MAGNESIUM BOROIDRURO CRISTALLINO
FR2877833B1 (en)	2007-10-12	CORRECTEUR OF LORDOSES
FR2919887B1 (en)	2009-10-09	CREMONE OR CREMONE-LOCK TYPE FERRIDE